stockportfolio.pro
DVA vs GH: Which Stock Is the Better Buy?
DaVita Inc. and Guardant Health, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — DVA vs GH, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| DaVita Inc. (DVA) | Guardant Health, Inc. (GH) | |
|---|---|---|
| Market cap | $15.1B | $17.4B |
| Revenue (latest FY) | $13.64B | $982.02M |
| Net income (latest FY) | $746.80M | $-416.28M |
| Revenue growth (5y CAGR) | 3.4% | 27.9% |
| Net margin | 5.5% | -42.4% |
| Return on equity | -114.7% | 419.2% |
| P/E ratio | 22.6 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 10 | 0 |
| Positive free cash flow | Yes | No |
See the full DVA vs GH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open DVA's full financials → Open GH's full financials →Frequently asked questions
Which is bigger, DVA or GH?
Guardant Health, Inc. is larger by market capitalization — $17.4B versus $15.1B.
Which grows faster, DVA or GH?
Over the last five fiscal years, Guardant Health, Inc. grew revenue faster — 27.9%/yr versus 3.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.